Clinical trial
A Phase 3 Extension Study to Evaluate the Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis
NCT06651281 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3 Extension Study to Evaluate the Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis
- Lead sponsor
- Merck Sharp & Dohme LLC
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- November 25, 2024
- Completion date
- December 17, 2037
- Enrollment
- 1,380 (estimated)
- Sites
- 37
Conditions
As the registry lists them; a condition with its own page is linked.